Article
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2006
Jackman David M, Yeap Beow Y, Sequist Lecia V, Lindeman Neal, Holmes Alison J, Joshi Victoria A, Bell Daphne W, Huberman Mark S, Halmos Balazs, Rabin Michael S, Haber Daniel A, Lynch Thomas J, Meyerson Matthew, Johnson Bruce E, Jänne Pasi A
Abstract excerpt
PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non-small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib. Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.